Drugmaker reverses course, plans to seek FDA approval for Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment...

Posted: Oct 23, 2019 3:24 AM
Updated: Oct 23, 2019 3:32 AM

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.

Phase 3 clinical studies of aducanumab were discontinued in March. The trials were halted because results of a futility analysis found they were unlikely to meet their primary goals at completion.

On Tuesday, Biogen announced that a new analysis, which included more patients, showed a significant reduction in clinical decline in one trial. Results for some patients in another study support those findings, as well.

The data showed that patients who received aducanumab experienced significant benefits on measures of cognition and function, including memory, orientation and language, according to Biogen.

"I really hope these new analyses pan out," said Dr. Richard Isaacson, director of the Alzheimer's Prevention Clinic at Weill Cornell Medicine in New York, who had patients in the original clinical studies.

"I'm not surprised that a reanalysis of the data showed something positive," he said, adding, "I do believe that there are going to be probably continued regulatory hurdles."

Additionally, the drug could be extremely expensive, Isaacson said.

"The complicated aspect here is I would not be surprised if additional analyses, with larger (numbers), with higher doses, do show signals in either the overall population or subgroup analysis, but is that going to be enough for the FDA to approve this from a regulatory perspective? Would payers reimburse it? I don't know, but I hope so," he said.

'We are hopeful'

The company Biogen said it will file an application with the FDA in early 2020 and will continue discussions with regulatory authorities in Europe and Japan. It will also offer access to aducanumab to eligible patients previously enrolled in the phase 3 studies.

"This is the result of groundbreaking research and is a testament to Biogen's steadfast determination to follow the science and do the right thing for patients," Biogen CEO Michel Vounatsos said in the company's announcement on Tuesday.

"We are hopeful about the prospect of offering patients the first therapy to reduce the clinical decline of Alzheimer's disease and the potential implication of these results for similar approaches targeting amyloid beta," he said.

The "amyloid hypothesis" says it's the accumulation of beta-amyloid in the brain that is the primary cause of the memory-destroying disease. The hypothesis has been the driving force behind Alzheimer's research for more than 20 years.

Yet most attempts to develop amyloid-targeting drugs in people with the disease have failed.

In late 2016, Eli Lilly's solanezumab failed to surpass placebo benefits in a Phase 3 trial of 2,100 patients. In 2013, Pfizer scrapped another antibody, bapineuzumab, when it didn't surpass placebo effects in another Phase 3 trial. Experts suggest that the advanced stages of Alzheimer's among study participants in both trials might have contributed to the failures.

Merck used a different approach to fight beta-amyloid in people with late-stage Alzheimer's with its BACE inhibitor verubecestat but admitted defeat in early 2017 after an independent study found that it had "virtually no chance" of working. A second attempt to treat earlier stages of Alzehimer's was also scrapped in February.

Johnson & Johnson's BACE inhibitor atabecestat, designed to slow cognitive decline in people at risk for Alzheimer's, was also scrapped in May 2018 when liver enzymes spiked in study participants.

Waiting in anticipation

Alzheimer's disease is the sixth leading cause of death in the United States. About 5.8 million people in the United States currently live with Alzheimer's, and that's projected to rise to nearly 14 million by 2050.

The Alzheimer's Association applauded Biogen for pursuing regulatory approval for aducanumab.

"The Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based on Phase 3 clinical trial results from the EMERGE and ENGAGE studies, and other related data, after finding a reduction of cognitive and functional decline in people taking the high dose," Maria Carrillo, chief science officer at the Alzheimer's Association, said in a written statement on Tuesday.

"We eagerly anticipate reviewing a full report of findings referenced in today's Biogen announcement."

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 154878

Reported Deaths: 2206
CountyCasesDeaths
Multnomah31824528
Washington21099212
Marion18373285
Clackamas13328175
Lane10200126
Jackson8315111
Umatilla763982
Deschutes593459
Yamhill376764
Linn357756
Malheur334458
Polk303942
Klamath278455
Douglas244754
Josephine232849
Benton232516
Jefferson195128
Coos144019
Union128119
Columbia124821
Wasco122026
Lincoln112820
Hood River106429
Morrow104614
Clatsop7756
Crook77518
Baker6507
Curry4246
Tillamook4142
Lake3746
Harney2736
Grant2221
Wallowa1424
Gilliam531
Sherman530
Wheeler221
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 3559311

Reported Deaths: 51794
CountyCasesDeaths
Los Angeles118923221241
Riverside2894503767
San Bernardino2860772783
Orange2607213982
San Diego2589823260
Santa Clara1102371777
Kern102627811
Fresno950151422
Sacramento929611464
Alameda802791241
Ventura77395834
San Joaquin665691082
Contra Costa62164674
Stanislaus55887946
Tulare47784746
Monterey42138327
San Mateo38872515
San Francisco34138398
Santa Barbara31763407
Solano30024164
Merced28915395
Sonoma28004298
Imperial26855589
Kings21951218
Placer19763232
San Luis Obispo19612227
Madera15414209
Santa Cruz14588183
Marin13136197
Yolo12787185
Shasta10969174
Butte10922160
El Dorado9095100
Napa899869
Sutter884597
San Benito575259
Yuba573336
Lassen560119
Tehama508152
Tuolumne394659
Nevada394074
Mendocino379643
Amador344841
Humboldt318033
Lake314140
Glenn221923
Colusa212813
Calaveras190547
Siskiyou174014
Inyo128736
Mono12114
Del Norte9875
Plumas6536
Modoc4524
Mariposa3957
Trinity3675
Sierra990
Alpine810
Unassigned00
Medford
Cloudy
40° wxIcon
Hi: 47° Lo: 36°
Feels Like: 36°
Brookings
Mostly Cloudy
40° wxIcon
Hi: 51° Lo: 33°
Feels Like: 40°
Medford
Cloudy
40° wxIcon
Hi: 27° Lo: 13°
Feels Like: 36°
Medford
Cloudy
40° wxIcon
Hi: 48° Lo: 35°
Feels Like: 36°
Klamath Falls
Mostly Cloudy
28° wxIcon
Hi: 37° Lo: 25°
Feels Like: 28°
Drying out and warming up
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events